Olimel N12

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, the active ingredients in Olimel N12, are an amino acid solution presented as an intravenous infusion for parenteral use. It supplies essential amino acids to support protein synthesis in patients who cannot receive enteral nutrition, such as those in critical care, postoperative recovery, or with gastrointestinal impairment.

GNH USA supplies Olimel N12 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through its regulated distribution network.

Olimel N12 provides a balanced mixture of essential and non‑essential amino acids for parenteral nutrition support.

- Total parenteral nutrition: supplies necessary amino acids to maintain nitrogen balance in patients unable to tolerate enteral feeding. - Post‑operative recovery: supports protein synthesis and wound healing in surgical patients with increased metabolic demand. - Critical illness and trauma: helps counteract catabolism and preserve lean body mass in intensive care patients.

Intravenous amino acid solutions may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion site pain or erythema: mild discomfort at the catheter insertion point. - Hypernatremia: elevated serum sodium due to electrolyte content. - Metabolic alkalosis: shift in acid‑base balance from amino acid metabolism. - Hyperglycemia: increased blood glucose when combined with glucose‑containing fluids. - Fever or chills: transient reaction during infusion. - Electrolyte disturbances: mild shifts in potassium, calcium or phosphate levels.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention. - Hepatic dysfunction: abnormal liver enzymes in susceptible patients. - Renal impairment: worsening kidney function due to nitrogen load. - Severe metabolic acidosis: rare but possible in patients with pre‑existing disorders. - Thrombophlebitis: inflammation of veins at the infusion site. - Sepsis: infection related to catheter contamination.

When using Olimel N12, clinicians should observe several precautionary measures to ensure patient safety and product integrity.

- Assess renal and hepatic function: evaluate baseline labs before initiating therapy. - Monitor plasma electrolytes: check sodium, potassium, calcium and phosphate regularly. - Adjust infusion rate in metabolic disorders: tailor dosing for patients with inborn errors of metabolism. - Avoid in known amino acid hypersensitivity: discontinue if allergic reaction occurs. - Use aseptic technique: maintain sterile conditions during preparation and administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amino acid infusions can interact with other medications or solutions, influencing electrolyte balance and metabolic outcomes.

Major Interactions (Avoid): - High‑dose potassium chloride: may cause dangerous hyperkalemia. - Loop diuretics: can exacerbate electrolyte losses when combined with amino acid solutions. - Insulin therapy with glucose‑containing fluids: increases risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: may increase protein catabolism, reducing effectiveness. - Parenteral lipid emulsions: can alter amino acid to lipid ratio, requiring adjustment. - Renal replacement therapy: may remove infused amino acids, affecting dosing. - Anticoagulants (heparin): may increase risk of bleeding at catheter site.